Loading...
Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
First line treatment of patients with castrate resistant prostate cancer (CRPC) primarily involves administration of docetaxel chemotherapy. Unfortunately, resistance to docetaxel therapy is an ultimate occurrence. Alterations in androgen receptor (AR) expression and signaling are associated mechani...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4114978/ https://ncbi.nlm.nih.gov/pubmed/25072314 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0103680 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|